share_log

基石藥業-B：截至二零二四年二月二十九日止月份之股份發行人的證券變動月報表

CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 29 FEBRUARY 2024

香港交易所 ·  Mar 6 03:30
Summary by Moomoo AI
基石藥業於2024年2月29日提交了最新的證券變動月報表給香港交易及結算所有限公司。報告顯示，截至2024年2月底，公司的法定/註冊股本結存維持在2,000,000,000股，每股面值0.0001美元，總股本為200,000美元，本月內無增減變動。此外，公司的股份期權計劃中，首次公開發售前激勵計劃的股份期權數目由上月的4,989,538減少156至4,989,382，而首次公開發售後僱員持股計劃的股份期權數目則由71,796,186減少857,571至70,938,615。報告中未提及有關股份的其他變動，並確認所有證券發行均已獲得董事會授權並符合相關法律規定。報告由董事李偉於2024年3月6日呈交。
基石藥業於2024年2月29日提交了最新的證券變動月報表給香港交易及結算所有限公司。報告顯示，截至2024年2月底，公司的法定/註冊股本結存維持在2,000,000,000股，每股面值0.0001美元，總股本為200,000美元，本月內無增減變動。此外，公司的股份期權計劃中，首次公開發售前激勵計劃的股份期權數目由上月的4,989,538減少156至4,989,382，而首次公開發售後僱員持股計劃的股份期權數目則由71,796,186減少857,571至70,938,615。報告中未提及有關股份的其他變動，並確認所有證券發行均已獲得董事會授權並符合相關法律規定。報告由董事李偉於2024年3月6日呈交。
KEYSTONE PHARMACEUTICALS SUBMITTED ITS LATEST MONTHLY STATEMENT OF CHANGES IN SECURITIES TO HONG KONG TRADING AND SETTLEMENT LIMITED ON 29 FEBRUARY 2024. The report shows that as of the end of February 2024, the company's regulated/registered share capital remained at 2,000,000,000 shares with a face value of $0.0001 per share and a total share capital of $200,000, with no increase or decrease during the month. In addition, the number of stock options in the Company's pre-IPO incentive plan decreased 156 to 4,989,382 from 4,989,538 in the previous month, and the number of stock options in the employee share plan after the initial public offering decreased from 71,796,186 to 857,571 to 70,938,615. The report does not mention other changes in the shares and confirms that all securities issuances have been authorized by the Board of Directors and comply with relevant legal requirements. The report was submitted by Director Li Wei on 6 March 2024.
KEYSTONE PHARMACEUTICALS SUBMITTED ITS LATEST MONTHLY STATEMENT OF CHANGES IN SECURITIES TO HONG KONG TRADING AND SETTLEMENT LIMITED ON 29 FEBRUARY 2024. The report shows that as of the end of February 2024, the company's regulated/registered share capital remained at 2,000,000,000 shares with a face value of $0.0001 per share and a total share capital of $200,000, with no increase or decrease during the month. In addition, the number of stock options in the Company's pre-IPO incentive plan decreased 156 to 4,989,382 from 4,989,538 in the previous month, and the number of stock options in the employee share plan after the initial public offering decreased from 71,796,186 to 857,571 to 70,938,615. The report does not mention other changes in the shares and confirms that all securities issuances have been authorized by the Board of Directors and comply with relevant legal requirements. The report was submitted by Director Li Wei on 6 March 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more